PHI 30/23 Consultation on two draft Cost Recovery Implementation Statements (CRIS) – 1 July 2023 to 30 June 2024

For administration of the Prescribed List of Benefits for Medical Devices and Human Tissue Products and the National Joint Replacement Registry

Date published:
PHI circular type:
Prescribed List announcement
Audience:
Health sector

Stakeholders are invited to provide feedback on the following draft Cost Recovery Implementation Statements (CRIS) 1 July 2023 – 30 June 2024:

Administration of the Prescribed List of Benefits for Medical Devices and Human Tissue Products (the Prescribed List), previously known as the Prostheses List

The draft CRIS contains further information on the revised cost recovery charges to align with the new listing pathways as part of the Prostheses List reform. It also describes the legislative changes required to support the administration of cost recovery arrangements relating to the Prescribed List.

National Joint Replacement Registry (NJRR)

The draft CRIS includes detailed activities that are planned for the NJRR for each financial year between 2023-2027; and the updated cost recovery arrangements to reflect the proposed new funding amount to the Australian Orthopaedic Association (AOA). Cost recovery of the NJRR supports Commonwealth funding to the AOA to administer the Registry (pending finalisation of new Grant Agreement between the Department and AOA).

The CRIS were last updated on 30 November 2022 to report the financial and non-financial results for the 2021-22 financial year. They also outlined financial forecasts for 2023-24 and future financial years.

Stakeholders can submit their feedback to HTAImprovement@health.gov.au by 25 May 2023.

The final CRIS documents will include a summary of the feedback received from stakeholders.